FDA Greenlights J&J's Controversial Diabetes Drug

Law360, Los Angeles (March 29, 2013, 10:00 PM EDT) -- The U.S. Food and Drug Administration said Friday that it had approved Johnson & Johnson's Invokana, the first in a new class of diabetes drugs, less than three months after announcing concerns about possible cardiovascular and bone risks.

Invokana, which consists of the drug canagliflozin, is the first sodium-glucose co-transporter 2 inhibitor, which allows glucose to pass out of the body, that the FDA has approved. Along with greenlighting the drug, the FDA announced that it is conducting five post-marketing studies to assess the drug's cardiovascular...
To view the full article, register now.